Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

12 Issues per year


IMPACT FACTOR 2013: 2.955
Rank 5 out of 29 in category Medical Laboratory Technology in the 2013 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR): 0.860
Source Normalized Impact per Paper (SNIP): 1.046

VolumeIssuePage

Issues

Haptocorrin in humans

Anne L. Morkbak1 / Steen S. Poulsen2 / Ebba Nexo3

1Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark and The Fertility Clinic Dronninglund, Aalborg University Hospital, Dronninglund, Denmark

2Department of Medical Anatomy, Panum Institute, University of Copenhagen, Copenhagen, Denmark

3Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark

Corresponding author: Ebba Nexo, Department of Clinical Biochemistry, Aarhus University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark Phone: +45-89-493083, Fax: +45-89-493060,

Citation Information: Clinical Chemical Laboratory Medicine. Volume 45, Issue 12, Pages 1751–1759, ISSN (Online) 14374331, ISSN (Print) 14346621, DOI: 10.1515/CCLM.2007.343, December 2007

Publication History

Received:
2007-07-10
Accepted:
2007-09-21
Published Online:
2007-12-08

Abstract

Background: Evolutionary haptocorrin is the youngest of the cobalamin-binding proteins. It evolved by duplication of the intrinsic factor gene and has been identified in most mammals examined. Its ability to bind both cobalamin and analogues is well established, but apart from that, our knowledge concerning its function and its distribution in adult and foetal life is limited. In this study, we present data on the tissue expression of haptocorrin and on the relation between analogues on haptocorrin and vitamin B12 status in humans.

Methods: Polyclonal antibodies towards haptocorrin were used to study the localisation in foetal and adult tissues by immunohistochemistry. Positive immunoreactions were primarily observed in exocrine glands, the gastrointestinal tract and the respiratory system. ELISA was used for measurement of holo- and total haptocorrin in blood samples from individuals diagnosed with vitamin B12 deficiency, based on measurement of methylmalonic acid (μmol/L) as evident (>0.75, n=61), suspected (0.29–0.75, n=155) or not present (<0.29, n=170). Cobalamins and holotranscobalamin were measured in the same individuals.

Results: Holohaptocorrin was considerably higher than holohaptocorrin-cobalamins (cobalamins minus holotranscobalamin). The median (25th–75th percentile, pmol/L) for holohaptocorrin analogues (holohaptocorrin minus holohaptocorrin-cobalamins) was higher in deficient [200 (130–240)] compared to the non-deficient [140 (80–200)] individuals (analysis of variance and Tukey's multiple comparison test, p<0.01).

Conclusions: Our results indicate that haptocorrin is widely distributed also in foetal tissues and suggest analogues to accumulate on haptocorrin in vitamin B12-deficient individuals, a result that warrants further studies employing methods directly measuring cobalamins and analogues attached to haptocorrin.

Clin Chem Lab Med 2007;45:1751–9.

Keywords: analogues; cobalamin; extra cellular fluids; foetal; immunohistochemistry

Comments (0)

Please log in or register to comment.